{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:19:26Z","timestamp":1766157566038},"reference-count":28,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The treatment of Gram-negative infections is increasingly compromised by the spread of resistance. With few agents currently in development, clinicians are now considering the use of unorthodox combination therapies for multidrug-resistant strains. Here we assessed the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of the novel lipoglycopeptide telavancin (TLV) when combined with colistin (COL) versus 13 Gram-negative type strains and 66 clinical isolates. Marked synergy was observed in either checkerboard (fractional inhibitory concentration index [FICI], &lt;0.5; susceptibility breakpoint index [SBPI], &gt;2) or time-kill assays (&gt;2-log reduction in viable counts compared with starting inocula at 24 h) versus the majority of COL-susceptible enterobacteria,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Stenotrophomonas maltophilia<\/jats:named-content>\n            , and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Acinetobacter baumannii<\/jats:named-content>\n            isolates, but only limited effects were seen against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            or strains with COL resistance. Using an Etest\/agar dilution method, the activity of TLV was potentiated by relatively low concentrations of COL (0.25 to 0.75 \u03bcg\/ml), reducing the MIC of TLV from &gt;32 \u03bcg\/ml to \u22641 \u03bcg\/ml for 35% of the clinical isolates. This provides further evidence that glycopeptide-polymyxin combinations may be a useful therapeutic option in the treatment of Gram-negative infections.\n          <\/jats:p>","DOI":"10.1128\/aac.05870-11","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:42:02Z","timestamp":1334018522000},"page":"3080-3085","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["<i>In Vitro<\/i>\n            Activity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens"],"prefix":"10.1128","volume":"56","author":[{"given":"Michael","family":"Hornsey","sequence":"first","affiliation":[{"name":"Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe, Staines, Middlesex, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Phee","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom"},{"name":"Division of Infection, Barts and The London NHS Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Wareham","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom"},{"name":"Division of Infection, Barts and The London NHS Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00079-11"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05298-11"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0031-1275525","article-title":"Epidemiology of infections acquired in intensive care units","volume":"32","author":"Doyle JS","year":"2011","unstructured":"DoyleJS BuisingKL ThurskyKA WorthLJ RichardsMJ. 2011. Epidemiology of infections acquired in intensive care units. Semin. Respir. Crit. Care Med. 32:115\u2013138.","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00922-10"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.024"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir202"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32833f0d3e"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00230-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01219-09"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/48.suppl_1.77","article-title":"Recommendations for susceptibility tests on fastidious organisms and those requiring special handling","volume":"48","author":"King A","year":"2001","unstructured":"KingA. 2001. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother. 48(Suppl. 1):77\u201380.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.186.13.4124-4133.2004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr262"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/519471","article-title":"Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"45","author":"Micek ST","year":"2007","unstructured":"MicekST. 2007. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3):S184\u2013S190.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp384"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01244-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq069"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan P","year":"2010","unstructured":"RattanaumpawanP LorsutthithamJ UngprasertP AngkasekwinaiN ThamlikitkulV. 2010. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother. 65:2645\u20132649.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-09"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.56.3.395-411.1992"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00405-08"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-09"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1469-0691.2011.03581.x","article-title":"In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii","volume":"18","author":"Vila-Farres X","year":"2011","unstructured":"Vila-FarresX. 2011. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin. Microbiol. Infect. 18:383\u2013387.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr069"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00268.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1021\/bi9008243","article-title":"Wasp mastoparans follow the same mechanism as the cell-penetrating peptide transportan 10","volume":"48","author":"Yandek LE","year":"2009","unstructured":"YandekLE PokornyA AlmeidaPF. 2009. Wasp mastoparans follow the same mechanism as the cell-penetrating peptide transportan 10. Biochemistry 48:7342\u20137351.","journal-title":"Biochemistry"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05870-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05870-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:16:43Z","timestamp":1645481803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05870-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1128\/AAC.05870-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05870-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2011-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}